Literature DB >> 24458131

Association of prostate size and perioperative morbidity in thulium:YAG vapoenucleation of the prostate.

Christopher Netsch1, Christian Tiburtius, Thorsten Bach, Sophie Knipper, Andreas J Gross.   

Abstract

OBJECTIVE: To evaluate the association between perioperative morbidity and prostate size in patients with benign prostatic obstruction treated with thulium:YAG vapoenucleation of the prostate (ThuVEP).
METHODS: 687 patients were prospectively analyzed. Prostate size was <40 ml in 196 (group A), 40-79 ml in 336 (group B) and ≥80 ml in 155 (group C) patients.
RESULTS: The mean prostate sizes were 27.94 ± 6.77, 54.38 ± 10.54 and 109.8 ± 28.31 ml for groups A, B and C, respectively (p < 0.001). Hemoglobin loss (g/dl) differed significantly among group A (1.09 ± 1.02), group B (1.28 ± 1.27) and group C (1.62 ± 1.49) (p < 0.001). The correlation between hemoglobin loss and prostate size was very weak in all patients (r = 0.13, p ≤ 0.001). Peak urinary flow rates and post-voiding residual urine improved significantly (p < 0.001) without differences among the groups. The incidence of complications was low and not different among the groups (acute urinary retention 8%, urinary tract infection 4.66%, secondary apical resection 2.91%, transfusion rate 2.03%).
CONCLUSIONS: Perioperative morbidity and micturition improvement are not associated with prostate size in ThuVEP.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24458131     DOI: 10.1159/000355105

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

Review 1.  Nomenclature in thulium laser treatment of benign prostatic hyperplasia: it's time to pull the rabbit out of the hat.

Authors:  Serena Maruccia; Irene Fulgheri; Emanuele Montanari; Stefano Casellato; Luca Boeri
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

2.  Prospective assessment of perioperative course in 2648 patients after surgical treatment of benign prostatic obstruction.

Authors:  Thorsten Bach; Felix Wölbling; Andreas J Gross; C Netsch; S Tauber; Tobias Pottek; Christian Wülfing; Claus Brunken
Journal:  World J Urol       Date:  2016-06-04       Impact factor: 4.226

Review 3.  Update on the current evidence for Tm:YAG vapoenucleation of the prostate 2014.

Authors:  C Netsch; T Bach; T R W Herrmann; A J Gross
Journal:  World J Urol       Date:  2014-10-10       Impact factor: 4.226

4.  Bipolar Transurethral Enucleation of the Prostate: Is it a size-independent endoscopic treatment option for symptomatic benign prostatic hyperplasia?

Authors:  Carolina Bebi; Matteo Turetti; Elena Lievore; Francesco Ripa; Lorenzo Rocchini; Matteo Giulio Spinelli; Elisa De Lorenzis; Giancarlo Albo; Fabrizio Longo; Franco Gadda; Paolo Guido Dell'Orto; Andrea Salonia; Emanuele Montanari; Luca Boeri
Journal:  PLoS One       Date:  2021-06-09       Impact factor: 3.240

5.  Clinical Outcome of Endoscopic Enucleation of the Prostate Compared With Robotic-Assisted Simple Prostatectomy for Prostates Larger Than 80 cm3 in Aging Male.

Authors:  Chen-Pang Hou; Yu-Hsiang Lin; Pei-Shan Yang; Phei-Lang Chang; Chien-Lun Chen; Kuo-Yen Lin; Horng-Heng Juang; Shu-Chuan Weng; Ke-Hung Tsui
Journal:  Am J Mens Health       Date:  2021 Nov-Dec

6.  Outcomes following Thulium vapoenucleation of large prostates.

Authors:  Shane M Pearce; Joseph J Pariser; Rena D Malik; Olufenwa J Famakinwa; Doreen E Chung
Journal:  Int Braz J Urol       Date:  2016 Jul-Aug       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.